Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes.
- Published In:
- Diabetes care, 48(12), 2127-2137 (2025)
- Authors:
- Fang, Yichen E, Paik, Julie M(5), Ortega-Montiel, Janinne(2), Tesfaye, Helen, Wexler, Deborah J, Patorno, Elisabetta
- Database ID:
- RPEP-10900
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10900APA
Fang, Yichen E; Paik, Julie M; Ortega-Montiel, Janinne; Tesfaye, Helen; Wexler, Deborah J; Patorno, Elisabetta. (2025). Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes.. Diabetes care, 48(12), 2127-2137. https://doi.org/10.2337/dc25-1840
MLA
Fang, Yichen E, et al. "Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes.." Diabetes care, 2025. https://doi.org/10.2337/dc25-1840
RethinkPeptides
RethinkPeptides Research Database. "Risk of Acute Pancreatitis and Biliary Events After Initiati..." RPEP-10900. Retrieved from https://rethinkpeptides.com/research/fang-2025-risk-of-acute-pancreatitis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.